Unadjusted rate of cardiovascular disease in relation to percentiles of maximal carotid intima-media thickness (IMT) or coronary artery calcium (CAC) score (The Multi-Ethnic Study of Atherosclerosis, 2000-2004). CI indicates confidence interval.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Folsom AR, Kronmal RA, Detrano RC, et al. Coronary Artery Calcification Compared With Carotid Intima-Media Thickness in the Prediction of Cardiovascular Disease Incidence: The Multi-Ethnic Study of Atherosclerosis (MESA). Arch Intern Med. 2008;168(12):1333–1339. doi:10.1001/archinte.168.12.1333
Coronary artery calcium (CAC) and carotid intima-media thickness (IMT) are noninvasive measures of atherosclerosis that consensus panels have recommended as possible additions to risk factor assessment for predicting the probability of cardiovascular disease (CVD) occurrence. Our objective was to assess whether maximum carotid IMT or CAC (Agatston score) is the better predictor of incident CVD.
A prospective cohort study of subjects aged 45 to 84 years in 4 ethnic groups, who were initially free of CVD (n = 6698) was performed, with standardized carotid IMT and CAC measures at baseline, in 6 field centers of the Multi-Ethnic Study of Atherosclerosis (MESA). The main outcome measure was the risk of incident CVD events (coronary heart disease, stroke, and fatal CVD) over a maximum of 5.3 years of follow-up.
There were 222 CVD events during follow-up. Coronary artery calcium was associated more strongly than carotid IMT with the risk of incident CVD. After adjustment for each other (CAC score and IMT) and traditional CVD risk factors, the hazard ratio of CVD increased 2.1-fold (95% confidence interval [CI], 1.8-2.5) for each 1–standard deviation (SD) increment of log-transformed CAC score, vs 1.3-fold (95% CI, 1.1-1.4) for each 1-SD increment of the maximum IMT. For coronary heart disease, the hazard ratios per 1-SD increment increased 2.5-fold (95% CI, 2.1-3.1) for CAC score and 1.2-fold (95% CI, 1.0-1.4) for IMT. A receiver operating characteristic curve analysis also suggested that CAC score was a better predictor of incident CVD than was IMT, with areas under the curve of 0.81 vs 0.78, respectively.
Although whether and how to clinically use bioimaging tests of subclinical atherosclerosis remains a topic of debate, this study found that CAC score is a better predictor of subsequent CVD events than carotid IMT.
Prospective epidemiologic studies have consistently documented that noninvasive measures of atherosclerosis, such as coronary artery calcium (CAC) and carotid intima-media thickness (IMT), are associated positively and strongly with future incidence of cardiovascular disease (CVD). For example, a meta-analysis recently identified relative risks of coronary heart disease (CHD) of 1.0, 1.9, 4.3, 7.2, and 10.8 for CAC values of 0, 1 to 112, 100 to 400, 400 to 999, and 1000 or greater, respectively.1 Another meta-analysis reported significant relative risks of CHD of 1.26 for myocardial infarction (MI) and 1.32 for stroke for each 1–standard deviation (SD) increment of common carotid artery IMT.2
Whether and how to use these screening tests in clinical practice remains a matter of debate. Some task forces have recommended that bioimaging tests for atherosclerosis be considered for patients at intermediate risk of CHD (10%-20% risk in 10 years), for whom preventive interventions are often uncertain.1,3 Another group recommended measuring CAC or IMT in all asymptomatic men aged 45 to 75 years and women aged 55 to 75 years as a guide to clinical decision making.4
Coronary artery calcium and IMT are only moderately correlated within individuals,5-9 so each test has some potential to be useful clinically to predict future CVD. Terry et al10 reported that CAC was associated more strongly than IMT with prevalent coronary artery stenosis. Brook et al11 confirmed this but found that an estimate of carotid plaque area predicted coronary stenosis somewhat more strongly than even CAC. Neither of these cross-sectional studies assessed CVD incidence. The prospective Rotterdam Study found that carotid plaques, increased IMT, aortic calcium, and low ankle-brachial blood pressure index predicted incident myocardial infarction (MI) fairly comparably, and the more subclinical measures present, the greater the risk.12 Their study did not examine CAC. Very recently, the first prospective study assessed the potential utility of measuring CAC vs IMT for global CVD risk prediction. Newman et al13 found that CAC and common carotid IMT similarly predicted CVD and CHD in adults 70 years or older, but IMT was the better predictor of stroke. Herein, we also address this question, prospectively, in the Multi-Ethnic Study of Atherosclerosis (MESA).
MESA recruited 6814 adults aged 45 to 84 years from the populations near 6 field centers (Baltimore, Maryland; Chicago, Illinois; Forsyth County, North Carolina; Los Angeles, California; New York, New York; and St Paul, Minnesota) to a baseline examination between July 2000 and September 2002.14 The study participants were white (38%), African American (28%), Hispanic (22%), and Chinese American (12%) and free of clinically recognized CVD and were drawn from households in geographically defined areas (5 centers) or in an occupational union (New York). MESA conducted 3 subsequent examinations of the cohort between 2002 and 2007. Institutional review boards at each site approved the study, and all participants gave written informed consent.
Centrally trained clinical teams collected information on cardiovascular risk factors during the baseline examination. They measured resting blood pressure 3 times in seated participants with a Dinamap model Pro 1000 automated oscillometric sphygmomanometer (Critikon, Tampa, Florida). A central laboratory measured total and high-density lipoprotein cholesterol and glucose levels from blood samples obtained after a 12-hour fast. We defined diabetes as a fasting glucose level of 126 mg/dL or greater (to convert to millimoles per liter, multiply by 0.0555) or use of hypoglycemic medication.
Scanning centers assessed CAC by chest computed tomography using either a cardiac-gated electron-beam computed tomography scanner (Chicago, Los Angeles, and New York field centers) or a multidetector computed tomography system (Baltimore, Forsyth County, and St Paul field centers). Certified technologists scanned all participants twice. A phantom of known physical calcium concentration was included in the field of view. A radiologist or cardiologist read all computed tomographic scans at a central reading center (Los Angeles Biomedical Research Institute at Harbor–UCLA Medical Center in Torrance, California) using an interactive scoring system similar to that used by Yaghoubi et al.15 The reader–work station interface identified and quantified CAC from images calibrated according to the readings of the calcium phantom. The Agatston score,16 which is a pseudo–continuous variable derived from plaque densities and their areas in all coronary arteries, was computed. We used the mean phantom-adjusted Agatston score for the 2 scans in all analyses. Carr et al17 have reported the details of the MESA computed tomographic scanning and interpretation methods. Each participant and his or her physicians were notified whether the CAC scores were below average, average, or above average for the participant's age. No recommendation was made about treatment.
Trained technicians in each field center performed B-mode ultrasonography of the right and left near and far walls of the internal carotid and common carotid arteries.18 They used the Logiq 700 ultrasound device (General Electric Medical Systems, Waukesha, Wisconsin) to record images. An ultrasound reading center (Department of Radiology, Tufts–New England Medical Center, Boston, Massachusetts) measured maximal IMT of the internal and common carotid sites as the mean of the maximum IMT of the near and far walls of the right and left sides. In addition, for this article, we created a composite z score for overall maximal IMT by summing the values of the 2 carotid IMT sites (if both were measured) after standardization (subtraction of the mean and division by the SD of each measure) and then dividing by the SD of the sum. If only 1 of the 2 measures was available, it was used. The resulting variable, hereafter referred to as z score maximum IMT, has a mean of 0 and an SD of 1. Each participant and his or her physicians were notified whether an accompanying Doppler assessment suggested significant carotid stenosis (≥50%), but no recommendation was made about treatment.
We followed the cohort for incident CVD events for a median of 3.9 years (maximum, 5.3 years). At intervals of 9 to 12 months, a telephone interviewer contacted each participant to inquire about interim hospital admissions, cardiovascular outpatient diagnoses, and deaths. To verify self-reported diagnoses, we requested copies of all death certificates and medical records for hospitalizations and outpatient cardiovascular diagnoses. We also conducted next-of-kin interviews for out-of-hospital cardiovascular deaths. We obtained records on an estimated 98% of reported hospitalized cardiovascular events and some information on 95% of reported outpatient diagnostic encounters.
Two physicians, blinded to the CAC and IMT data, independently reviewed and classified CVD events and assigned incidence dates. If, after review and adjudication, disagreements persisted, a full mortality and morbidity review committee made the final classification. MESA criteria for events were adopted from the Atherosclerosis Risk in Communities Study, the Cardiovascular Health Study, and the Women's Health Initiative. Reviewers classified MI as definite, probable, or absent, based primarily on combinations of symptoms, electrocardiographic findings, and levels of cardiac biomarkers (generally, troponins or creatine kinase myocardial band). Reviewers graded angina based on their clinical judgment as definite, probable, or absent. Probable angina required symptoms of ischemia, as well as documentation that a physician had diagnosed and treated angina. Definite angina also required objective diagnostic evidence of CHD. In this article, we only included definite angina (n = 76) plus probable angina when accompanied by coronary revascularization (n = 5). The reviewers classified CHD or CVD death as present or absent based on hospital records and interviews with families. Definite fatal CHD required an MI within 28 days of death, chest pain within the 72 hours before death, or a history of CHD and the absence of a known nonatherosclerotic or noncardiac cause of death. Neurologists reviewed and classified stroke as present if there was a focal neurologic deficit lasting 24 hours or until death, with a clinically relevant lesion on brain imaging and no nonvascular cause.
For this report, we defined incident CVD as CHD (definite and probable MI, definite CHD death, resuscitated cardiac arrest, definite angina, and probable angina associated with coronary revascularization), stroke (fatal or nonfatal), or other atherosclerotic CVD death. Follow-up went from the baseline examination until the first CVD event, loss to follow-up, death, or January 12, 2005, whichever came first.
From the 6814 MESA participants, we excluded 77 who were missing both of the carotid IMT measures, 5 who were discovered to have had CVD events before baseline, and 34 with no follow-up data, leaving 6698 participants for analysis. For most analyses, we either (1) categorized carotid IMT and CAC into 3 groups (the bottom 50% and the 2 upper quartiles) to accommodate the fact that 50% of participants had a CAC score of 0 or (2) treated IMT and the natural logarithm (ln) of (CAC score + 1) as continuous variables. The ln(CAC score + 1) transformation better normalized the CAC distribution. We used Cox proportional hazard regression to estimate hazard ratios (HRs). We performed tests for nonproportional hazards using Shoenfeld residuals; all results were nonsignificant. Covariates for multivariable models included age (continuous), sex, race/ethnicity (4 groups), smoking (current, former, or never), diabetes (yes or no), blood pressure (6 categories according to the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, including medications),19 high-density lipoprotein and total cholesterol level (continuous), and use of lipid-lowering medication (yes or no). We compared the strength of the association for IMT vs CAC score based on the relative size of their HRs and the corresponding χ2 test or z score of the HRs. We also compared IMT and CAC associations with receiver operating characteristic curves modeling carotid IMT and ln(CAC score + 1) as continuous variables in Cox models. In the Figure, rates were calculated for “low, medium, and high” values of z score maximum IMT and CAC score using intervals as previously described. All analyses were performed using STATA 9.2 (StataCorp, College Station, Texas) statistical software.
The MESA sample for this analysis comprised 6698 adults aged 45 to 84 years at baseline (3161 men and 3537 women). During 23 735 person-years of follow-up, we identified 222 incident CVD events (159 CHD events [61 MI, 81 angina, 3 resuscitated cardiac arrest, 13 CHD deaths]; 59 stroke events [3 of which included a CHD event]; and 7 other atherosclerotic CVD deaths). Of the MESA sample, 50% had detectable CAC. The mean (SD) value was 2.2 (2.5) for ln(CAC score + 1), 1.07 (0.60) mm for maximum internal carotid IMT, 0.87 (0.19) mm for maximum common carotid IMT, and 0.00 (1.00) for z score maximum IMT.
As given in Table 1, the 3 measures of carotid IMT were all positively associated with incident CVD, with age-, race/ethnicity-, and sex-adjusted HRs for the highest vs lowest quartile of 3.3 (95% confidence interval [CI], 2.1-5.2) for the maximum internal carotid IMT, 2.3 (95% CI, 1.4-3.8) for the maximum common carotid IMT, and 3.8 (95% CI, 2.2-6.4) for the z score maximum IMT (all P < .001). The remaining IMT analyses therefore focused on z score maximum IMT. For CAC score (Table 1), the HRs of CVD increased across categories, with the age-, race/ethnicity-, and sex-adjusted HR being 6.0 (95% CI, 3.9-9.1) for the highest CAC score quartile vs a CAC score of 0 (P < .001). The results for CHD risk (data not shown) were similar. For reference to recommended clinical cut points for CAC score,1,3 the age-, race/ethnicity-, and sex-adjusted HRs for CAC scores of 0, 1 to 99, 100 to 399, and 400 or greater were 1 [Reference], 4.7 (95% CI, 2.5-8.7), 11.5 (95% CI, 6.2-21.5), and 16.1 (95% CI, 8.5-30.8), respectively (data not shown in tables).
When put in the same model, CAC score was more strongly associated with both CVD and CHD compared with IMT (Table 2). The multivariable-adjusted HRs of CVD and CHD per 1-SD increment were 1.9 (95% CI, 1.6-2.2) and 2.3 (95% CI, 1.9-3.8), respectively, for ln(CAC score + 1), compared with 1.2 (95% CI, 1.0-1.3) and 1.1 (95% CI, 1.0-1.3) for z score maximum IMT. Furthermore, the z scores were larger and P values were smaller for the CAC association. In contrast, for stroke, only z score maximum IMT was statistically significant (P = .01) with multivariable-adjusted HR of 1.3 (95% CI, 1.1-1.7), while the HR for ln(CAC + 1) was 1.1 (95% CI, 0.8-1.4).
A categorical analysis (Table 3) also suggested that CAC score was a better predictor of incident CVD and CHD than was IMT. For example, the multivariable-adjusted HRs of CHD for the highest quartile vs lowest 50th percentile were 8.2 (95% CI, 4.5-15.1; P < .001) for CAC and 1.7 (95% CI, 1.1-2.7; P = .07) for z score maximum IMT.
In supplemental research, we restricted our analyses to subjects at intermediate CHD risk, based on a Framingham risk score of 1% to 2% per year (n = 1841, with 54 CHD events). Among them, the multivariable-adjusted HRs of CHD per 1-SD increment were 2.4 (95% CI, 1.7-3.3; P < .001) for ln(CAC score + 1) and 1.3 (95% CI, 1.0-1.6; P < .05) for z score maximum IMT when both were included in the model. In the same subgroup at intermediate Framingham risk, for CVD (81 events), the multivariable-adjusted HRs were 1.8 (95% CI, 1.4-2.2; P < .001) for ln(CAC score + 1) and 1.4 (95% CI, 1.1-1.6; P = .001) for z score maximum IMT.
The Figure shows crude rates of incident CVD by 9 joint categories of z score maximum IMT and CAC score. Rates of CVD were between 1% and 2% per year for those with (1) a moderate level of CAC and high IMT or (2) a high level of CAC and low IMT. Rates of CVD were greater than 2% per year for those with a high level of CAC and either a moderate or high level of IMT. Those with a CAC score of 0 and either low or moderate IMT had almost no events during this follow-up period. Findings for CHD were similar (data not shown).
Findings from receiver operating characteristic curve analysis suggested that CAC score was a better predictor of CVD incidence than was carotid IMT. With the multiple risk factors in the model for CVD, the area under the curve (AUC) was 0.772 (95% CI, 0.74-0.80). After adding z score maximum IMT, the AUC was 0.782 (95% CI, 0.75-0.81); after substituting CAC score for IMT, the AUC was 0.808 (95% CI, 0.78-0.83); and after including both IMT and CAC score, the AUC was 0.811 (95% CI, 0.78-0.84). A similar receiver operating characteristic curve analysis for CHD produced AUCs of 0.771 (95% CI, 0.74-0.80) for risk factors alone, 0.782 (95% CI, 0.75-0.82) for risk factors plus IMT, 0.823 (95% CI, 0.79-0.85) for risk factors plus CAC score, and 0.824 (95% CI, 0.79-0.85) for risk factors plus CAC score and IMT.
This prospective analysis of the MESA cohort who were initially free of symptomatic CVD found that carotid maximum IMT and CAC score, 2 measures of subclinical atherosclerosis, predicted future CVD events. However, CAC score was the better predictor for CHD and total CVD. Intima-media thickness was a modestly better predictor of stroke than CAC score, although there were few stroke events. The associations observed were consistent with those reported by meta-analyses of prospective studies of each subclinical measure of atherosclerosis studied separately.1,2 They were somewhat inconsistent with a small prospective study in elderly people, in which common carotid IMT was similiar to CAC in predicting CVD and CHD.13 It may be that IMT becomes more predictive of CVD in old age, but the smaller sample size of that study also may have limited its ability to show differences between CAC and IMT associations with CVD.
Although previous consensus statements indicated that CAC score and IMT are global atherosclerosis measures and either might be used clinically for refinement of CVD risk assessment,4,20 our data suggest that in asymptomatic 45- to 84-year-old US adults, CAC score may be the better choice over IMT. As judged by proportional hazards modeling and by the AUC, CAC score added more to CVD prediction, beyond traditional risk factors, than did IMT. Coronary artery calcium was also associated with CHD more strongly than IMT within the group of individuals at intermediate risk, for whom a subclinical atherosclerosis assessment may be most appropriate.1,3,20 When more CVD events accrue in MESA, we can more thoroughly address the issue of what novel measures (eg, CAC score, IMT, C-reactive protein level, and others) might improve CVD risk prediction in intermediate-risk patients.
The modestly better prediction of stroke by IMT and clearly better prediction of CHD by CAC score likely reflects their different vascular territories. The potential choice between measuring CAC or IMT or neither in preventive cardiology depends on other considerations as well (eg, differences in radiation exposure, cost, and availability). The CAC score may be most relevant in the United States, where CHD is common. If risk of stroke in families with histories of early stroke were a concern, then carotid IMT may be very relevant. Also, in MESA, there are substantial ethnic differences in CAC score (highest in whites),21 and to a lesser degree for IMT (highest in African Americans),22 which may have an impact on clinical use.
Strengths of this study include its multiethnic sample, standardized subclinical atherosclerosis assessments and risk factor measurements, and its reliance on symptomatic end points to avoid detection bias related to CVD events being diagnosed more readily in subjects with known subclinical atherosclerosis. Limitations include, first, the relatively short follow-up period and the relatively small number of strokes to date. Results could be different for long-term CVD prediction, especially as this population ages and the ratio of strokes to CHD events increases. Second, the shapes of distributions differ for IMT and CAC, with many 0 values for CAC score. However, our analyses using both categorical and continuous measures of IMT and CAC placed them on a more comparable footing. Third, although all end points were symptomatic, we included both “hard” CHD (MI and CHD death) and “soft” CHD (angina) to provide adequate statistical power. Fourth, for ethical reasons, we felt compelled to report high CAC and IMT values to participants and refer them to their physicians. More participants were referred for high CAC score (17%) than for high IMT (1%), which could have affected our findings if participants changed risk factors differentially. Yet, this seems unlikely, since a clinical trial suggested that telling patients their CAC score does not motivate significant health behavior change.23
In conclusion, although whether and how to use bioimaging tests for subclinical atherosclerosis remains a topic of debate, this study found that CAC score was a better predictor of subsequent CVD events than was carotid IMT.
Corresponding Author: Aaron R. Folsom, MD, Division of Epidemiology & Community Health, School of Public Health, University of Minnesota, 1300 S Second St, Ste 300, Minneapolis, MN 55454-1015 (firstname.lastname@example.org).
Accepted for Publication: November 26, 2007.
Author Contributions: Dr Folsom had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Folsom, Kronmal, Detrano, O’Leary, Bild, Bluemke, Shea, and Tracy. Acquisition of data: Folsom, Kronmal, Detrano, O’Leary, Budoff, Liu, Shea, Szklo, Tracy, Watson, and Burke. Analysis and interpretation of data: Folsom, Kronmal, O’Leary, Bild, Budoff, Liu, and Burke. Drafting of the manuscript: Folsom, Kronmal, and O’Leary. Critical revision of the manuscript for important intellectual content: Kronmal, O’Leary, Bild, Bluemke, Budoff, Liu, Shea, Szklo, Tracy, Watson, and Burke. Statistical analysis: Kronmal and Liu. Obtained funding: Kronmal, O’Leary, Bluemke, Shea, Tracy, and Burke. Administrative, technical, and material support: Kronmal, O’Leary, Bild, Shea, and Tracy. Study supervision: O’Leary, Budoff, Shea, and Watson.
Financial Disclosure: Dr O’Leary serves as consultant to Sankyo Pharma, Sanofi-Aventis, GlaxoSmithKline, Eli Lilly, Schering-Plough, Pfizer, AstraZeneca, and Merck and owns stock in Medpace. Dr Budoff has received honoraria for speaking on behalf of General Electric.
Funding/Support: This research was supported by grants N01-HC-95159 through N01-HC-95169 from the National Heart, Lung, and Blood Institute.
Role of the Sponsor: The National Heart, Lung, and Blood Institute staff had input in the design and conduct of this study; the collection, management, analysis, and interpretation of the data; and the preparation of the manuscript.
Additional Contributions: We thank the other investigators, the staff, and the participants of the MESA Study for their valuable contributions. A full list of participating MESA investigators and institutions can be found at http://www.mesa.nhlbi.org.